ClinicalTrials.gg
Not yet recruitingNCT07439146PNEUMIOTUpdated Feb 27, 2026

Risk of Pneumonia in Intubated Patients in Emergency Situations

An observational study in Pneumonia and Orotracheal Intubation, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Pneumonia with a site in France — 18 open to participants now, 20 under way, 3 of them phase 3. Pneumonia · France.

Planned enrollment
15th of 56
600 · median 227
Started
2026
with 1 other
Observational
56 of 138
12 open now
Primary completion
2026-12
later than 12 of 19 live
Registered
137th of 138
by date

Among the 138 studies in Pneumonia with a site in France, this one is the 15th largest by planned enrollment of the 56 observational ones that give a count, is one of 2 that started in 2026, is one of 56 observational ones, reaches primary completion later than 12 of the 19 other live ones, and was the 137th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

18 of the 138 studies in Pneumonia with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Pneumonia with a site in France, or all of them as a file.
02

Study summary

Orotracheal intubation in emergency medicine is a vital procedure for ensuring adequate oxygenation and ventilation in patients with respiratory distress or in shock. However, this procedure exposes patients to complications such as pneumonia. In the matter of fact, the urgency of the procedure means that it is not possible to wait until the patient's stomach is empty. Pneumonia significantly increase patient morbidity and mortality. Therapeutic management must be early and appropriate to improve the patient's prognosis.

The aim of this study is to compare the rate of pneumonia occurring in patients intubated in emergency situations with that in patients intubated in non-emergency situations in all 2024. Health data will only collected from patient's medical records.

03

Conditions studied

  • Pneumonia
  • Orotracheal Intubation

Browse trials for

Keywords

  • Orotracheal intubation in emergency
  • Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population is patient intubated in emergency situation and patients intubated in non-emergency situation following to the admission of intensive care in 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult man or woman
  • Emergency and non-emergency intubated patient in 2024
  • Patient hospitalized in intensive care following intubation in 2024

Exclusion criteria

Exclusion Criteria:

  • Patient under guardianship, curatorship or safeguard of justice
  • Pregnant woman
  • Refusal to participate
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intubated patients in emergency situations

    Health data will be collected only with medical's record of intubated patients in emergency situation in 2024.

  • Intubated patients in non emergency situations

    Health data will be collected only with medical's record of intubated patients in non emergency situation in 2024.

06

What researchers measure

Primary outcomes

  1. Pneumonia rate in 48 hours after the start of orotracheal intubation.

    Rate of pneumonia occuring within 48 hours of the start of orotracheal intubation.

    Time frame: Hour 48

Secondary outcomes

  1. Pneumonia rate occuring 48 hours after the start of orotracheal intubation.

    Rate of pneumonia occuring more than 48 hours after the start of orotracheal intubation.

    Time frame: 3 months

  2. Duration of mechanical ventilation

    Duration of mechanical ventilation

    Time frame: Up to the end of mechanical ventilation (assessed up to 1 month)

  3. Duration of stay in intensive care

    Duration of stay in intensive care

    Time frame: Up to intensive care discharge (assessed up to 1 month)

  4. Duration of hospital stay

    Duration of hospital stay

    Time frame: Up to hospital discharge (assessed up to 3 months)

  5. Mortality rate

    Mortality rate

    Time frame: Inclusion + 1 year

  6. Type of bacteria responsible for pneumonia

    The bacterial species responsible for pneumonia will be identified using biological samples (blood, urine, bronchial secretions) taken from patients in both groups. The identification of bacterial species will be carried out in the laboratory.

    Time frame: The day of the diagnosis of pneumonia (assessed up to 1 month)

  7. Type of antibiotic administered for pneumonia

    Type of antibiotic administered for pneumonia in each group

    Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)

  8. Antibiotic doses administered for pneumonia

    Comparison of antibiotic doses in g or mg administered in each group

    Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)

  9. Duration of antibiotic treament for pneumonia

    Duration of antibiotic treament for pneumonia in each group

    Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)

07

Study locations

6 sites
  • CH Aurillac
    Aurillac, 15000, France
  • CHU de Clermont-Ferrand, Clermont-Ferrand
    Clermont-Ferrand, France
  • CH du Puy en Velay
    Le Puy-en-Velay, 43000, France
    • Adrien ROBERT · Contactadrien.robert@ch-lepuy.fr · No phone number
    • Adrien ROBERT · Principal investigator
    • Angelo Giordano KWAKYE AGYEMANG · Sub investigator
  • CH de Montluçon
    Montluçon, 03100, France
  • CH de Moulins
    Moulins, 03000, France
  • CH de Vichy
    Vichy, 03200, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 27, 2026
StartEst.
Feb 9, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07439146
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Feb 9, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Jean-Baptiste BOUILLON-MINOIS
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion